Skip to main content
Explore URMC
menu

Ovarian Cancer: Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Research Question:
What are good and bad effects of adding atezolizumab to the usual chemotherapy (liposomal doxorubicin) and to the usual chemotherapy with bevacizumab?

Basic Study Information

Purpose:
This study has 3 study groups, a computer will assign you to a study group by chance. There is an equal chance of receiving each treatment. This is done by chance, because no one knows if one study group is better or worse than the others. Group 1 will get an experimental chemotherapy treatment (liposomal doxorubicin and atezolizumab), group 2 will get an experimental chemotherapy treatment (liposomal doxorubicin and bevacizumab plus atezolizumab), and group 3 will get a usual chemotherapy treatment for this type of cancer (liposomal doxorubicin and bevacizumab). The liposomal doxorubicin will be given into your vein over approximately 60 minutes. The bevacizumab will be given into your vein over approximately 90 minutes initially, then faster at later visits if administration goes smoothly at the slower rates. The atezolizumab will be given into your vein over approximately 60 minutes initially, then faster at later visits if administration goes smoothly at the slower rates. Treatment will be given on days 1 and 15 of each 28-day period. This period of time is called a cycle, which is a regular schedule of treatment with periods of rest in between.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02839707?term=GY009&rank=1
Study Reference #: CGYO18021

Lead Researcher (Principal Investigator)

Lead Researcher: Richard Moore

Study Contact Information

Study Coordinator: Laura Mitchell
Phone: (585) 275-7763
Email: Laura_Mitchell@URMC.Rochester.edu

Additional Study Details

Return to Search